ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
ImmuCell (Nasdaq: ICCC) has announced that its 2024 Annual Meeting of Stockholders will be held virtually on June 13, 2024, at 9:30 AM ET. The meeting will be conducted via telephone conference call and live audio webcast, not in person. Stockholders of record as of April 15, 2024, can participate by dialing specific toll-free numbers or accessing the webcast. Participation in the Q&A session post-meeting will be to the telephone call. A replay will be available until June 19, 2024. Stockholders are encouraged to vote in advance via proxy. More information is available on the company's website and SEC filings.
- The virtual format provides greater accessibility for stockholders, potentially increasing participation.
- Stockholders can participate from anywhere, offering flexibility and convenience.
- Replay of the meeting is available for seven days, ensuring all stockholders can access the meeting content.
- Encouragement to vote in advance ensures that stockholder input is considered even if they cannot attend the meeting.
- Virtual-only format may limit engagement and interaction compared to in-person meetings.
- Participation in the informal Q&A session is restricted to phone call attendees, potentially limiting comprehensive engagement.
- Stockholders who prefer in-person interactions may find the virtual format less satisfactory.
PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on April 26, 2024.
The Annual Meeting will be held by remote communication in the form of a telephone conference call and a live audio webcast, rather than as an in-person event. Stockholders of record of the Company’s common stock at the close of business on April 15, 2024, are invited to participate in the Annual Meeting by dialing (844) 855-9502 toll free or (412) 317-5499 for international access or by accessing the live audio webcast at https://app.webinar.net/znQpX7rqZLm. Participation via the live audio webcast will be in listen-only mode. Participation in the informal Q&A session, which will take place after the formal business of the meeting is concluded, will be limited to the telephone conference call connection.
A meeting replay will be available for seven days after the meeting by dialing (877) 344-7529 toll free or (412) 317-0088 for international access, using replay access code: 7085899 until June 19, 2024.
Stockholders, regardless of their plans to attend the virtual-only meeting, are encouraged to vote and submit their proxies in advance of the Annual Meeting using one of the methods described in the proxy materials. Stockholders may continue to use the voting instruction form or proxy card provided, and no additional action is required to be taken by stockholders who have already submitted their proxy. Stockholders that would like to vote at the Annual Meeting (instead of by proxy) should contact the Company’s Voting Inspector in advance of the meeting at (207) 878-2770 Ext. 0 or via email at: mail@immucell.com to arrange to vote during the meeting.
Investors are encouraged to review the Company’s Form 10-Q for the three-month period ended March 31, 2024 that was filed with the SEC on Tuesday, May 14, 2024 and its updated Corporate Presentation slide deck that provides an overview of the Company’s business and is available under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. For more information about the Annual Meeting, including the matters to be voted on during the Annual Meeting, please see the Company’s Notice of Annual Meeting of Stockholders and its Proxy Statement, which are available, along with the 2023 Annual Report on Form 10-K, at www.immucell.com.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without an FDA-required milk discard or meat withhold that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO |
| ImmuCell Corporation | |
| (207) 878-2770 | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| (602) 889-9700 | |
| iccc@lythampartners.com |
FAQ
When is ImmuCell's 2024 Annual Meeting of Stockholders?
How can stockholders participate in ImmuCell's 2024 Annual Meeting?
What is the stock symbol for ImmuCell?
How can I dial into ImmuCell's 2024 Annual Meeting?
Can stockholders ask questions during the virtual Annual Meeting?
What is the replay access code for ImmuCell's 2024 Annual Meeting?
Until when is the Annual Meeting replay available?
How can stockholders vote in advance of the Annual Meeting?
